Stocklytics Platform
Asset logo for symbol ACHL
Achilles Therapeutics plc
ACHL49
$1.18arrow_drop_down0.42%-$0.00
Penny Stock
Asset logo for symbol ACHL
ACHL49

$1.18

arrow_drop_down0.42%

Performance History

Chart placeholder
Key Stats
Open$1.19
Prev. Close$1.19
EPS-1.66
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$48.70M
PE Ratio-
LOWHIGH
Day Range1.15
1.21
52 Week Range0.68
1.76
Ratios
Revenue-
EBITDA Margin %-
EPS-1.66

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Achilles Therapeutics plc (ACHL)

Achilles Therapeutics plc (ACHL) is a UK-based clinical-stage biopharmaceutical company specializing in the development of immunotherapies for the treatment of cancer. The company's primary focus is on the development of personalized T cell therapies that target specific mutations in a patient's tumor. These therapies involve the extraction of T cells from a patient's blood, which are then genetically engineered to recognize and attack cancer cells carrying the targeted mutation. This personalized approach aims to improve the effectiveness of cancer treatment and reduce the risk of recurrence.
Achilles Therapeutics plc has made significant progress in its research and development efforts. The company has successfully completed several preclinical and clinical studies, demonstrating the safety and efficacy of its T cell therapies. These positive results have attracted the attention of investors and industry experts, leading to increased market interest in Achilles Therapeutics plc.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Iraj Ali
Headquarters
London
Employees
234
Exchange
NASDAQ
add Achilles Therapeutics plc to watchlist

Keep an eye on Achilles Therapeutics plc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Achilles Therapeutics plc's (ACHL) price per share?

The current price per share for Achilles Therapeutics plc (ACHL) is $1.19. The stock has seen a price change of -$0 recently, indicating a -0.42% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Achilles Therapeutics plc (ACHL)?

For Achilles Therapeutics plc (ACHL), the 52-week high is $1.76, which is 48.52% from the current price. The 52-week low is $0.68, the current price is 74.26% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Achilles Therapeutics plc (ACHL) a growth stock?

Achilles Therapeutics plc (ACHL) has shown an average price growth of -2.21% over the past three years. It has received a score of 19 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Achilles Therapeutics plc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Achilles Therapeutics plc (ACHL) stock price performance year to date (YTD)?

As of the latest data, Achilles Therapeutics plc (ACHL) has a year-to-date price change of 3.95%. Over the past month, the stock has experienced a price change of 16.18%. Over the last three months, the change has been 19.85%. Over the past six months, the figure is 41.16%.
help

Is Achilles Therapeutics plc (ACHL) a profitable company?

Achilles Therapeutics plc (ACHL) has a net income of -$69.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$75.26M. Furthermore, the EBITDA is -$65.9M.
help

What is the market capitalization of Achilles Therapeutics plc (ACHL)?

Achilles Therapeutics plc (ACHL) has a market capitalization of $48.7M. The average daily trading volume is 1.18, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level